1. Caring for people with severe mental disorders: a national plan of research to improve services. National Institute of Mental Health, DHHS Pub. no. (ADM) 91-1762. Washington, DC: U.S. Government Printing Office, 1991.

2. The contribution of pharmaceutical companies: what's at stake for America. Boston MA: Boston Consulting Group, September, 1993.

3. Data fact sheet: morbidity from coronary heart disease in the United States. Washington, DC: National Institutes of Health, May, 1992.

4. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J. Health Econ 1991 Feb;10(2):107-142.

5. DiMasi JA, Bryant NR, Lasagna L. New drug development in the United States from 1963 to 1990. Clin Pharmacol Ther 1991 May;50(5):471-486.

6. DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States, 1963 to 1992. Clin Pharmacol Ther 1994 Jun;55(6):609-622.

7. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry. PharmacoEcon 1995;7(2):152-169.

8. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995;58(1):1-14.

9. DiMasi JA. A new look at United States drug development and approval times. Amer J Ther 1996;3(9):1-11.

10. DiMasi JA, Manocchia M. Initiatives to speed new drug development and regulatory review: the impact of FDA-sponsor conferences. Drug Inf J 1997;31(3):771-788.

11. Discoveries in Biological Psychiatry. Ayd FJ, Blackwell B, eds. Philadelphia: Lippincott, 1970.

12. Drug Facts and Comparisons. St. Louis: Facts and Comparisons, 1993.

13. Faust RE, Harris MR, Lee KI. Factors which can harm the patient: economic restraints on research and development in the pharmaceutical industry. In: L'Etang H, ed. Regulation and restraint in contemporary medicine in the UK and USA London: Published jointly by the Royal Society of Medicine and MacMillan Press, 1983.

14. Fein R. Economics of mental illness: a report to the staff director, Jack R. Ewalt. New York, NY: Basic Books, 1958.

15. Fitton A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. PharmacoEcon 1993 Aug;4(2):131-156.

16. Freedman DX, Stahl SM. Pharmacology: policy implications of new psychiatric drugs. Health Aff (Millwood) 1992 Fall;11(3):157-163.

17. Glick ID, Lecrubier Y, Montgomery SA, Vinar O, Klein DF. Efficacious and safe psychotropics not available in the United States. Psych Ann 1996;26(6):354-361.

18. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993 Nov;54(11):405-418.

19. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: a neglected major illness. J Clin Psychiatry 1993;54:419-424.

20. Halliday RG, Walker SR, Lumley CE. R&D philosophy and management in the world's leading pharmaceutical companies. J Pharm Med 1992;2:139-154.

21. Hansen RW. The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. In: R.I. Chien, ed. Issues in pharmaceutical economics. Lexington, MA: DC Heath, 1979;151-187.

22. Health care reform for Americans with severe mental illnesses. Washington DC: National Mental Health Advisory Council, March 3, 1993.

23. James B. The future of the multinational pharmaceutical industry to1990. New York: Wiley, 1977.

24. Kane JM. Obstacles to clinical research and new drug development in schizophrenia. Schizophrenia Bulletin 1991;17(2):353-356.

25. Kaitin KI, Mattison N, Northington FK, Lasagna L. The drug lag: an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987. Clin Pharmacol Ther 1989;46(2):121-138.

26. Kaitin KI, Walsh HL. Are initiatives to speed the new drug approval process working? Drug Inf J 1992;26:341-349.

27. Kaitin KI, Manocchia MA. The new drug approvals of 1993, 1994, and 1995: trends in drug development. Amer J Ther 1997;4(1):46-54.

28. Kaitin KI. The Prescription Drug User Fee Act of 1992 and the new drug development process. Amer J Ther 1997;4(5):167-172.

29. Kessler DA, Hass AE, Feiden KL, Lumpkin M., Temple R. Approval of new drugs in the United States: comparison with the United Kingdom, Germany, and Japan. JAMA 1996;276(22):1826-1831.

30. Klein DF. Psychotropic drug development: challenge and promise Biol Psychiatry 1990 May;27(10):1061-1064.

31. Klein DF. Improvement of phase III drug trials by intensive phase II work. Neuropsychopharmacology 1991 Jun;4(4):251-258.

32. The market for psychotropic drugs. Scrip May 22, 1992;1720:26.

33. Landefeld JS, Seskin EP. The economic value of life: linking theory to practice. Am J Pub Health 1982 Jun;72(6):555-566.

34. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150(11):1630-1638.

35. Rice DP, Kalman S, Miller LS, Dunnmeyer S. The economic costs of alcohol and drug abuse and mental illness, 1985. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, 1990.

36. Rice DP. Cost of musculoskeletal conditions. In: Praemer A, Furner S, Rice DP, eds. Musculoskeletal conditions in the United States. Chicago: American Academy of Orthopedic Surgeons, 1992.

37. Schizophrenia market worth $2 billion by 2002. Marketletter May 17, 1993;20(20):15.

38. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987 Jan-Feb;102(1):5-17.

39. Shulman SR, Kaitin KI. The Prescription Drug User Fee Act of 1992: a five-year experiment for industry and the FDA. PharmacoEcon 1996;9:121-133.

40. Steinwachs DM, Kasper JD, Skinner EA. Patterns of use and costs among severely mentally ill people. Health Aff (Millwood) 1992 Fall;11(3):178-185.

41. Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer D. The economic burden of depression. Gen Hosp Psychiatry 1986 Nov;8(6):387-94.

42. Tucker SA, Blozan C, Coppinger P. The outcome of research on new molecular entities commencing clinical research in the years 1976-1978. Rockville, MD: Food and Drug Administration, Office of Planning and Evaluation, Economics Staff, OPE Study 77, May, 1988.

43. Vinar O, Klein DF, Potter WZ, Gause EM. A survey of psychotropic medications not available in the United States Neuropsychopharmacology 1991 Dec;5(4):201-217.

44. Wardell WM. Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther 1973 Sep/Oct;14(5):773-790.

45. Wardell WM. The drug lag revisited: comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976. Clin Pharmacol Ther 1978;24:499-524.

46. Wardell WM. History of drug discovery, development, and regulation. In Chien RI, ed. Issues in Pharmaceutical Economics. Lexington MA: DC Heath, 1979;3-11.

47. Wardell WM, DiRaddo J, Trimble, AG. Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976. Clin Pharmacol Ther 1980 Aug;28(2):270-277.